Inhibition of EZH2 in human GBM cell lines results in decreased cell proliferation (Suva et al., 2009), and in other GBMs, EZH2 knockdown results in derepression of BMPRIB, which may reduce tumorigenicity (Lee et al., 2008). This evidence concerns the gene EZH2 and glioblastoma.